278 related articles for article (PubMed ID: 11709727)
1. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Hermanto U; Zong CS; Wang LH
Oncogene; 2001 Nov; 20(51):7551-62. PubMed ID: 11709727
[TBL] [Abstract][Full Text] [Related]
2. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
3. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
4. Estradiol rapidly activates Akt via the ErbB2 signaling pathway.
Stoica GE; Franke TF; Wellstein A; Czubayko F; List HJ; Reiter R; Morgan E; Martin MB; Stoica A
Mol Endocrinol; 2003 May; 17(5):818-30. PubMed ID: 12554767
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Wang LH; Chan JL; Li W
Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506
[TBL] [Abstract][Full Text] [Related]
6. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
7. Growth factor-stimulated phosphorylation of Akt and p70(S6K) is differentially inhibited by LY294002 and Wortmannin.
Adi S; Wu NY; Rosenthal SM
Endocrinology; 2001 Jan; 142(1):498-501. PubMed ID: 11145615
[TBL] [Abstract][Full Text] [Related]
8. CRBP suppresses breast cancer cell survival and anchorage-independent growth.
Kuppumbatti YS; Rexer B; Nakajo S; Nakaya K; Mira-y-Lopez R
Oncogene; 2001 Nov; 20(50):7413-9. PubMed ID: 11704871
[TBL] [Abstract][Full Text] [Related]
9. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Cortés MA; Cariaga-Martinez AE; Lobo MV; Martín Orozco RM; Motiño O; Rodríguez-Ubreva FJ; Angulo J; López-Ruiz P; Colás B
Carcinogenesis; 2012 Jun; 33(6):1169-77. PubMed ID: 22461520
[TBL] [Abstract][Full Text] [Related]
10. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
11. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
12. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
14. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
[TBL] [Abstract][Full Text] [Related]
15. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production.
Salh B; Wagey R; Marotta A; Tao JS; Pelech S
J Immunol; 1998 Dec; 161(12):6947-54. PubMed ID: 9862729
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
McDonald GT; Sullivan R; Paré GC; Graham CH
Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.
Wang H; Liu XB; Chen JH; Wang QQ; Chen JP; Xu JF; Sheng CY; Ni QC
Exp Mol Pathol; 2014 Oct; 97(2):191-201. PubMed ID: 25036402
[TBL] [Abstract][Full Text] [Related]
18. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.
Bacus SS; Altomare DA; Lyass L; Chin DM; Farrell MP; Gurova K; Gudkov A; Testa JR
Oncogene; 2002 May; 21(22):3532-40. PubMed ID: 12032855
[TBL] [Abstract][Full Text] [Related]
19. Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells.
Nguyen KT; Wang WJ; Chan JL; Wang LH
Oncogene; 2000 Nov; 19(47):5385-97. PubMed ID: 11103940
[TBL] [Abstract][Full Text] [Related]
20. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
